VIXOTRIGINE, раксатригин , راكساتريجين , 维索曲静 ,

It’s only fair to share… VIXOTRIGINE Molecular FormulaC18H19FN2O2 Average mass314.354 Da раксатригин , راكساتريجين , 维索曲静 , (5R)-5-{4-[(2-Fluorobenzyl)oxy]phényl}-L-prolinamide 10287 2-Pyrrolidinecarboxamide, 5-[4-[(2-fluorophenyl)methoxy]phenyl]-, (2S,5R)- 934240-30-9 [RN] QQS4J85K6Y Raxatrigine UNII:QQS4J85K6Y Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker.[4]Following this, vixotrigine …

Omidenepag isopropyl, オミデネパグイソプロピル

It’s only fair to share… Omidenepag isopropyl DE-117 Glycine, N-(6-((((4-(1H-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)-, 1-methylethyl ester [[6-[[[4-(Pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)amino]methyl]pyridin-2-yl]amino]acetic acid isopropyl ester C26H28N6O4S, 520.6033, CAS: 1187451-19-9 APPROVED 2018/9/21 PMDA, JAPAN 2018, Eybelis Antiglaucoma, Prostaglandin E2 receptor agonist, Treatment of Open-Angle Glaucoma and Ocular Hypertension Originator Ube Industries Developer Santen Pharmaceutical Class Eye disorder therapies; Pyrazoles; Pyridines; Small molecules; Sulfonamides Mechanism of Action Prostaglandin E EP2 receptor agonists Registered Glaucoma; Ocular hypertension …

FDA approves first treatment Gamifant (emapalumab) specifically for patients with rare and life-threatening type of immune disease

It’s only fair to share… FDA approves first treatment Gamifant (emapalumab)  specifically for patients with rare and life-threatening type of immune disease  The U.S. Food and Drug Administration today approved Gamifant (emapalumab) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease …

Lumateperone

It’s only fair to share… Lumateperone Molecular FormulaC24H28FN3O Average mass393.497 Da 4-((6bR,10aS)-3-Methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 1-Butanone, 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)- 1-(4-fluorophenyl)-4-{4-methyl-1,4,12-triazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-5,7,9(16)-trien-12-yl}butan-1-one 313368-91-1 [RN] 70BSQ12069, Lumateperone, PHASE 3, ITI-007 4- methylbenzenesulfonate. SALT Molecular Formula: C31H36FN3O4S Molecular Weight: 565.704 g/mol (6bR,10aS)-8-[4-(4-Fluorophenyl)-4-oxobutyl]-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3‘,4’:4,5]pyrrolo[1,2,3-de]quinoxalin-8-ium 4-methylbenzenesulfonate 1187020-80-9 [RN] 1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-, 4-methylbenzenesulfonate (1:1) ITI-007 tosylate JIE88N006O Lumateperone tosylate [USAN] UNII:JIE88N006O ITI 007 Originator Bristol-Myers Squibb Develope rIntra-Cellular Therapies Class Antidepressants; Antipsychotics; Pyrroles; Quinoxalines; Sleep disorder …

Nemorexant

It’s only fair to share… Nemorexant ACT-541468, UNII LMQ24G57E9 [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] LMQ24G57E9 Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- Originator Actelion Pharmaceuticals Developer Idorsia Pharmaceuticals Class Sleep disorder therapies Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists Phase III Insomnia 19 Oct 2018 Idorsia Pharmaceuticals plans a phase I trial for Liver disorders (Hepatic impairment) in November 2018 (PO) (NCT03713242) 09 Oct …

Eflornithine, эфлорнитин , إيفلورنيثين , 依氟鸟氨酸 , エフロルニチン

It’s only fair to share… Eflornithine DFMO, RMI-71782ATC:P01CX03, BRN 2250529 / HSDB 7923 / MDL 71782 / RFI 7178 / RMI 71782 Ornithine, 2-(difluoromethyl)- UNII:ZQN1G5V6SR ZQN1G5V6SR эфлорнитин [Russian] [INN] إيفلورنيثين [Arabic] [INN] 依氟鸟氨酸 [Chinese] [INN] エフロルニチン 5551 67037-37-0 [RN] 70052-12-9 CAS a-Difluoromethylornithine (RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid Use:hirsutism treatment inhibitor of ornithine decarboxylase Chemical name:2-(difluoromethyl)-dl-ornithine Formula:C6H12F2N2O2, MW:182.17 g/mol CAS-RN:67037-37-0 LD50:>3000 mg/kg (M, i.p.); >5000 mg/kg (M, p.o.); 1364 μg/kg (R, intracerebral) Eflornithine, also known as …

Pirlindole

It’s only fair to share… Pirlindole Molecular FormulaC15H18N2 Average mass226.317 Da 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- 2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino[3,2,1-jk]carbazole 4615 60762-57-4 [RN] FREE FORM, 16154-78-2 (hydrochloride) 12-methyl-1,4-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-9(16),10,12,14-tetraene 8-Methyl-2,3,3a,4,5,6-hexahydro-1H-pyrazino[3,2,1-jk]carbazole UNII:V39YPH45FZ V39YPH45FZ INNOVATOR Russian Academy of Medical Sciences For the treatment of major depression. Pirlindole is a reversible inhibitor of monoamine oxidase A (RIMA) which was developed and is currently used in Russia as an antidepressant. It …

Isosorbide-2-acetate

It’s only fair to share… Spectral Data for 1 MS (ESI): calcd for [M + Na]+, 211.11; found, 211.11. IR (KBr) cm–1: 1732.08 (C═O), 3398.57 (−OH). 1H NMR (400 MHz, CD3OD): δ 5.11 (d, J = 3.6 Hz, 1H), 4.76 (s, 1H), 4.54 (t, J = 4.6 Hz, 1H), 4.49 (d, J = 4.4 Hz, 1H), 4.27 (td, J = 6.7, 5.1 Hz, 1H), …

Caplacizumab, カプラシズマブ Cablivi is the first therapeutic approved in Europe, for the treatment of a rare blood-clotting disorder

It’s only fair to share… Cablivi is the first therapeutic approved in Europe, for the treatment of a rare blood-clotting disorder On September 03, 2018, the European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is …

USFDA approval to Lumoxiti (moxetumomab pasudotoxtdfk) a new treatment for hairy cell leukemia

It’s only fair to share… USFDA approval to Lumoxiti is a new treatment for hairy cell leukemia On September 13, 2018, the U.S. Food and Drug Administration approved Lumoxiti (moxetumomab pasudotoxtdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory Hairy Cell Leukemia (HCL) who have received at least two …